novartis glp-1 receptor agonist weight management diabetes treatments How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments Adverse Effects of GLP-1 Receptor

January 9, 2026: MDLs for Ozempic and other GLP-1 Drugs Grow There are now two separate MDLs for injuries from Ozempic and other GLP-1 drugsone MDL for vision loss caused by NAION and one MDL for other injuries

In clinical studies targeting obesity, particularly in the phase 3 trials based on the SURPASS program, tirzepatide demonstrated outstanding weight reduction benefits, with some patients achieving a weight loss of up to 22.5%

With the accumulation of trial and real-world data, these analyses are becoming increasingly feasible

For millions of frustrated dieters, GLP - 1 drugs might seem like an almost magical solution

Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnstrom M, Moris L, Miliotis T, Forsberg GB, Riserus U, Lind L, Oscarsson J